MTR: GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification,
Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic
Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)
Summary
GLOBAL &
USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market
Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business
Strategies, Industry Trends, and Pipeline Analysis)” is a comprehensive report
on the cancer biomarker industry and its impact on the health system. This
report tackles the growing market interest in oncogenic biomarkers,
personalized medicine, companion diagnostics and the associated market
environment.
Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets.
Get Full Report With Table Of Contents at http://marketstoreports.com/products/global-usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipeline-analysis
Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets.
Get Full Report With Table Of Contents at http://marketstoreports.com/products/global-usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipeline-analysis
One of the most import aspects of biomarkers is their use to
diagnose and assess the progress of disease states in patients. As quantitative
markers, these agents also offer the ability to monitor response to certain
drug treatments and so are important in the area of personalized medicine.
Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.
This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics
Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.
This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.
In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics
Table of contents
Get Full Report With Table Of Contents at http://marketstoreports.com/products/global-usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipeline-analysis
Executive Summary 13 1.1 Objectives of Report 13 1.2 Data Sources and
Methodology 15 1.3 Key Findings and Observations 15 1.3.1 What Makes Cancer
Biomarkers so Important for the Healthcare Industry? 15 1.3.2 What Technologies
are Used to Identify Novel Biomarkers? 16 1.3.3 Increase in Cancer Prevalence
is Propelling the Oncogenic Biomarker Market 16 1.3.4 Global and US Economic
Impact of Cancer 16 1.3.5 How Cancer Biomarkers are Revolutionizing Cancer
Treatment 17 1.3.6 What are the most Significant and Strategic Cancer
Biomarkers? 17 1.3.7 Global Biomarker Test Market Analysis 18 1.3.8 Global
Cancer Biomarker Market Analysis 18 1.3.9 Oncology Biomarker Market Main
Industry Players 19 1.3.10 Drivers, Restraints, Opportunities and Challenges of
the Cancer Biomarker Market 19
2.0 Global Burden of Cancer 20 2.1 Global Cancer Statistics 20 2.2 Lung Cancer Globally 25 2.3 Lung Cancer Mutation Analysis 28 2.4 Colorectal (Bowel) Cancer Globally 29 2.5 Prostate Cancer Globally 31 2.6 Breast Cancer Globally 33 2.7 Global Economic Impact of Cancer 39 2.8 Cancer in the USA 40 2.9 Breast Cancer in the US 43 2.10 Lung Cancer in the US 44 2.11 Colorectal Cancer in the US 45 2.12 Prostate Cancer in the US 50 2.13 Skin Cancer in the US 52
3.0 Oncogenic Biomarkers – An Overview 54 3.1 Biomarker Discovery to Clinical Validation 56 3.2 Specific Technologies Used in Biomarker Discovery 57 3.2.1 Proteomics 57 3.2.2 Mass Spectrometry Based Technologies 57 3.2.3 Principles of Diagnostic Mass Spectrometry 58 3.2.4 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) 58 3.2.5 Nano LC-MS/MS 59 3.2.6 MALDI-TOF 59 3.3 Glycomics 60 3.4 Metabolomics 61 3.5 Peptidomics 62 3.5.1 Enzyme-Linked Immunosorbent Assay (ELISA) 62 3.6 Selected (Multiple) Reaction Monitoring 66 3.7 DNA Based Techniques 67 3.7.1 Microarrays 67 3.7.2 Small Molecule Real Time (SMRT) DNA Sequencing 69 3.7.3 Digital PCR 69 3.7.4 Next Generation Sequencing 70
GLOBAL & USA CANCER BIOMARKER MARKET to 2018
3.7.5 Second-Generation Sequencing Platforms 71 3.7.6 Whole Genome Sequencing 71 3.7.7 Epigenomics 72 3.7.8 Bioinformatics and Next Generation Sequencing 72 3.7.9 Third Generation Sequencing 72
4.0 Biomarker Validation 73 4.1 Introduction 73 4.2 Phases of Biomarker Validation 73 4.3 Biomarker Validation and Clinical Trials 75
5.0 Current and Prospective Oncogenic Biomarkers 77 5.1 Catalogue of Somatic Mutations in Cancer (COSMIC) 77 5.2 P53 Transcription Factor Oncogenic Mutations 78 5.2.1 Current Clinical Trials Investigating P53 as an Oncogenic Biomarker 83 5.3 Epidermal Growth Factor
2.0 Global Burden of Cancer 20 2.1 Global Cancer Statistics 20 2.2 Lung Cancer Globally 25 2.3 Lung Cancer Mutation Analysis 28 2.4 Colorectal (Bowel) Cancer Globally 29 2.5 Prostate Cancer Globally 31 2.6 Breast Cancer Globally 33 2.7 Global Economic Impact of Cancer 39 2.8 Cancer in the USA 40 2.9 Breast Cancer in the US 43 2.10 Lung Cancer in the US 44 2.11 Colorectal Cancer in the US 45 2.12 Prostate Cancer in the US 50 2.13 Skin Cancer in the US 52
3.0 Oncogenic Biomarkers – An Overview 54 3.1 Biomarker Discovery to Clinical Validation 56 3.2 Specific Technologies Used in Biomarker Discovery 57 3.2.1 Proteomics 57 3.2.2 Mass Spectrometry Based Technologies 57 3.2.3 Principles of Diagnostic Mass Spectrometry 58 3.2.4 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) 58 3.2.5 Nano LC-MS/MS 59 3.2.6 MALDI-TOF 59 3.3 Glycomics 60 3.4 Metabolomics 61 3.5 Peptidomics 62 3.5.1 Enzyme-Linked Immunosorbent Assay (ELISA) 62 3.6 Selected (Multiple) Reaction Monitoring 66 3.7 DNA Based Techniques 67 3.7.1 Microarrays 67 3.7.2 Small Molecule Real Time (SMRT) DNA Sequencing 69 3.7.3 Digital PCR 69 3.7.4 Next Generation Sequencing 70
GLOBAL & USA CANCER BIOMARKER MARKET to 2018
3.7.5 Second-Generation Sequencing Platforms 71 3.7.6 Whole Genome Sequencing 71 3.7.7 Epigenomics 72 3.7.8 Bioinformatics and Next Generation Sequencing 72 3.7.9 Third Generation Sequencing 72
4.0 Biomarker Validation 73 4.1 Introduction 73 4.2 Phases of Biomarker Validation 73 4.3 Biomarker Validation and Clinical Trials 75
5.0 Current and Prospective Oncogenic Biomarkers 77 5.1 Catalogue of Somatic Mutations in Cancer (COSMIC) 77 5.2 P53 Transcription Factor Oncogenic Mutations 78 5.2.1 Current Clinical Trials Investigating P53 as an Oncogenic Biomarker 83 5.3 Epidermal Growth Factor
Get Full Report With Table Of Contents
at http://marketstoreports.com/products/global-usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipeline-analysis
Receptor (EGFR) 84 5.3.1 EGFR-Activating and Resistance Mutations 85
5.3.2 Clinically Validated Resistance Mechanisms to EGFR Inhibitors 86 5.3.3
Current Strategies to Defeat Resistance to EGFR-Mediated Cancer Therapeutics 87
5.4 BRCA- Mutant Cancers 87 5.5 PARP-Inhibitors are Making a Comeback 90 5.5.1
Olaparib – A Pipeline PARP-Inhibitor 90 5.5.2 Niraparib (MK4827) in Phase III
trials 91 5.5.3 Rucaparib 91 5.5.4 Veliparib 91 5.5.5 Novel Biomarkers in the
PARP-Inhibitor Response Pathway 92 5.6 PTEN – Current Leader in Pipeline Onocogenic
Biomarkers 92 5.7 Ataxia Telangiectasia Mutated (ATM) – A Pipeline Target 93
5.8 TMPRSS2-ERG – A Promising Prostate Cancer Biomarker 94 5.9 MiR-17/92
Cluster – The Oncomir with Biomarker Potential 95 5.9.1 Altered MiR-17/92
Expression Correlates with Cancer Pathogenesis 95 5.9.2 MiR-17/92 Cluster and
Colorectal Cancer 96 5.9.3 MiR-17/92 Cluster and Breast Cancer 96 5.9.4
MiR-17/92 Cluster and Ovarian Cancer 97 5.9.5 MiR-17/92 Cluster and Lung Cancer
97 5.9.6 MiR-17/92 Cluster and Renal Cancer 97 5.9.7 MiR-17/92 Cluster and Head
and Neck Cancer 97 5.9.8 MiR-17/92 Cluster and Pancreatic Cancer 97 5.9.9
MiR-17/92 Cluster and Liver Cancer 98 5.9.10 MiR-17/92 Cluster and Acute
Myeloid Leukaemia 98 5.9.11 MiR-17/92 Cluster and B-Cell Lymphoma 98 5.9.12 MiR-17/92
Cluster and B-Cell Chronic Lymphocytic Leukemia 98 5.9.13 Transcriptional
Regulators of MiR-17/92 Cluster 98 5.9.14 Significant Molecular Targets of
MiR-17/92 99
6.0 Cancer Biomarker Test Market Analysis 2013-2018 101 6.1 Economic Burden of Cancer Worldwide 101 6.2 Economic Burden of Cancer in the US 101 6.3 Global Biomarker Test Market Analysis 102 6.4 Oncology Biomarkers Dominate the Biomarker Market 103 6.5 Global Cancer Profiling Technology Market 105 6.6 Global Cancer Biomarker Market Analysis 105 6.7 Market Share of Oncology Market Within Total Biomarker Market 108 6.8 US Cancer Biomarker Market 108 6.9 Oncology Biomarker Market is Fuelled by Year-on-Year Expansion of Research Publications 109
GLOBAL & USA CANCER BIOMARKER MARKET to 2018
6.10 Proteomic and Genomic Technologies are Preferred as Methods of Detection by End-Users 114
7.0 Oncology Biomarker Market Main Industry Players 115 7.1 23andMe 115 7.2 Affymetrix 116 7.3 Ambry Genetics 118 7.4 Astex Pharmaceuticals 119 7.5 Atossa Genetics 121 7.6 CuraGen 122 7.7 Celera Corporation (Quest Diagnostics) 122 7.8 Celldex Therapeutics 122 7.9 deCode Genetics (Amgen) 124 7.10 Foundation Medicine 124 7.11 Illumina 125 7.12 Genelex 126 7.13 Genomic Health 126 7.14 Myriad 126 7.15 Nodality 127 7.16 OriGene Technologies 130 7.17 Randox 130 7.18 Qiagen 131
6.0 Cancer Biomarker Test Market Analysis 2013-2018 101 6.1 Economic Burden of Cancer Worldwide 101 6.2 Economic Burden of Cancer in the US 101 6.3 Global Biomarker Test Market Analysis 102 6.4 Oncology Biomarkers Dominate the Biomarker Market 103 6.5 Global Cancer Profiling Technology Market 105 6.6 Global Cancer Biomarker Market Analysis 105 6.7 Market Share of Oncology Market Within Total Biomarker Market 108 6.8 US Cancer Biomarker Market 108 6.9 Oncology Biomarker Market is Fuelled by Year-on-Year Expansion of Research Publications 109
GLOBAL & USA CANCER BIOMARKER MARKET to 2018
6.10 Proteomic and Genomic Technologies are Preferred as Methods of Detection by End-Users 114
7.0 Oncology Biomarker Market Main Industry Players 115 7.1 23andMe 115 7.2 Affymetrix 116 7.3 Ambry Genetics 118 7.4 Astex Pharmaceuticals 119 7.5 Atossa Genetics 121 7.6 CuraGen 122 7.7 Celera Corporation (Quest Diagnostics) 122 7.8 Celldex Therapeutics 122 7.9 deCode Genetics (Amgen) 124 7.10 Foundation Medicine 124 7.11 Illumina 125 7.12 Genelex 126 7.13 Genomic Health 126 7.14 Myriad 126 7.15 Nodality 127 7.16 OriGene Technologies 130 7.17 Randox 130 7.18 Qiagen 131
Get Full Report With Table Of Contents
at http://marketstoreports.com/products/global-usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipeline-analysis
8.0 Oncology Biomarker Market Products and Kits 133 8.1 Oncology
Companion Diagnostic Tests 133 8.1.1 HER2 Tests in Breast Cancer Patients 133
8.2 23andMe 135 8.3 Affymetrix 139 8.4 Ambry Genetics 140 8.4.1 BRCAPlus 140
8.4.2 BreastNext 141 8.4.3 CancerNext 141 8.4.4 ColoNext 141 8.4.5 OvaNext 142
8.4.6 PancNext 142 8.4.7 RenalNext 142 8.4.8 Hereditary Diffuse Gastric Cancer
Test 145 8.5 Astex Pharmaceuticals 150 8.6 Atossa Genetics 150 8.6.1 Mammary Aspirate
Specimen Cytology Test (MASCT™) 150 8.6.2 ForeCYTE Breast Health Test (SM) 150
8.6.3 ArgusCYTE Breast Health Test(SM) 151 8.6.4 FullCYTE Breast Health Test
151 8.6.5 NextCYTE Breast Health Test 151 8.7 BioMerieux 151 8.7.1 THxID™ -BRAF
Kit 151 8.8 Celera (Quest Diagnostics) 151 8.9 deCode Genetics 153 8.9.1 deCODE
Breast Cancer™ 153 8.9.2 deCODE Prostate Cancer™ 153 8.9.3 deCODE AF™ 153 8.9.4
deCODE Complete™ 153 8.9.5 deCODE Cancer™ 154 8.9.6 deCODE Services 154 8.10
Foundation Medicine 155 8.10.1 FoundationOne 155
GLOBAL & USA CANCER BIOMARKER MARKET to 2018
8.10.2 FoundationOne Heme 155 8.11 Illumina 157 8.11.1 Illumina New-Generation Sequencing Technology 157 8.11.2 Illumina HiSeq 2500/1500 158 8.11.3 Illumina HiSeq 2000/1000 158 8.11.4 Genome Analyzer IIx 159 8.11.5 Illumina MiSeq 159 8.11.6 Illumina HiScanHQ 159 8.11.7 Illumina HiScan and iScan Array 159 8.12 Genelex 160 8.13 Genomic Health 160 8.13.1 Oncotype DX Breast Cancer Test 160 8.13.2 Oncotype DX Colon Cancer Test 161 8.13.3 Oncotype DX Prostate Cancer Assay 161 8.14 Myriad Genetics 163 8.14.1 BRACAnalysis® 163 8.14.2 Comprehensive BRACAnalysis® 165 8.14.3 BRACAnalysis® Rearrangement Test (BART) 165 8.14.4 Single Site BRACAnalysis® 165 8.14.5 Multisite 3 BRACAnalysis® 165 8.14.6 COLARIS®/COLARIS AP® 166 8.14.7 MELARIS® 166 8.14.8 PANEXIA® 166 8.14.9 OnDose® 167 8.14.10 PREZEON™ 167 8.14.11 THERAGUIDE® 5FU 167 8.14.12 Prolaris® 167 8.15 Nodility 168 8.16 OriGene 168 8.16.1 TissueScan™ Cancer cDNA Arrays 168 8.17 Randox 172 8.17.1 Tumor PSA Marker Array 172 8.17.2 Tumor Marker Array 3 172 8.17.3 KRAS/ BRAF/PIK3CA Array 172 8.18 Qiagen 173 8.18.1 Genotyping Products 173 8.18.2 QIAsymphony Platform 175 8.18.3 Therascreen® EGFR RGQ PCR Kit 176 8.18.4 Therascreen KRAS RGQ PCR System 176 8.18.5 Therascreen® IDH1/2 test 176 8.19 Roche 177 8.19.1 Cobas® EGFR Mutation Test 177
9.0 Market Participant Financial and Business Strategy Analysis 178 9.1 23andMe 178 9.2 Affymetrix 180 9.3 Astex Pharmaceuticals (Otuska Pharamceutical) 189 9.4 Atossa Genetics 192 9.5 BioMerieux 195 9.6 Celera (Quest Diagnostics) 200 9.7 Celldex Therapeutics 206 9.8 deCode Genetics (Amgen) 207 9.9 Foundation Medicine 208 9.10 Illumina 210
GLOBAL & USA CANCER BIOMARKER MARKET to 2018
8.10.2 FoundationOne Heme 155 8.11 Illumina 157 8.11.1 Illumina New-Generation Sequencing Technology 157 8.11.2 Illumina HiSeq 2500/1500 158 8.11.3 Illumina HiSeq 2000/1000 158 8.11.4 Genome Analyzer IIx 159 8.11.5 Illumina MiSeq 159 8.11.6 Illumina HiScanHQ 159 8.11.7 Illumina HiScan and iScan Array 159 8.12 Genelex 160 8.13 Genomic Health 160 8.13.1 Oncotype DX Breast Cancer Test 160 8.13.2 Oncotype DX Colon Cancer Test 161 8.13.3 Oncotype DX Prostate Cancer Assay 161 8.14 Myriad Genetics 163 8.14.1 BRACAnalysis® 163 8.14.2 Comprehensive BRACAnalysis® 165 8.14.3 BRACAnalysis® Rearrangement Test (BART) 165 8.14.4 Single Site BRACAnalysis® 165 8.14.5 Multisite 3 BRACAnalysis® 165 8.14.6 COLARIS®/COLARIS AP® 166 8.14.7 MELARIS® 166 8.14.8 PANEXIA® 166 8.14.9 OnDose® 167 8.14.10 PREZEON™ 167 8.14.11 THERAGUIDE® 5FU 167 8.14.12 Prolaris® 167 8.15 Nodility 168 8.16 OriGene 168 8.16.1 TissueScan™ Cancer cDNA Arrays 168 8.17 Randox 172 8.17.1 Tumor PSA Marker Array 172 8.17.2 Tumor Marker Array 3 172 8.17.3 KRAS/ BRAF/PIK3CA Array 172 8.18 Qiagen 173 8.18.1 Genotyping Products 173 8.18.2 QIAsymphony Platform 175 8.18.3 Therascreen® EGFR RGQ PCR Kit 176 8.18.4 Therascreen KRAS RGQ PCR System 176 8.18.5 Therascreen® IDH1/2 test 176 8.19 Roche 177 8.19.1 Cobas® EGFR Mutation Test 177
9.0 Market Participant Financial and Business Strategy Analysis 178 9.1 23andMe 178 9.2 Affymetrix 180 9.3 Astex Pharmaceuticals (Otuska Pharamceutical) 189 9.4 Atossa Genetics 192 9.5 BioMerieux 195 9.6 Celera (Quest Diagnostics) 200 9.7 Celldex Therapeutics 206 9.8 deCode Genetics (Amgen) 207 9.9 Foundation Medicine 208 9.10 Illumina 210
Get Full Report With Table Of Contents
at http://marketstoreports.com/products/global-usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipeline-analysis
1.0 GLOBAL
& USA CANCER BIOMARKER MARKET to 2018
9.11 Genelex 213 9.12 Genomic Health 213 9.13 Myriad 214 9.14 Nodality 218 9.15 Qiagen 220
10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market 225 10.1 Drivers of Oncogenic Biomarker Market 225 10.1.1 High demand and Unmet Need Enhances the Global Biomarker Market 225 10.1.2 Biomarkers are Highly Specific Diagnostic and Prognostic Clinical Tools 225 10.1.3 Increasing Cancer Prevalence Globally 226 10.1.4 FDA Support Increases Biomarker Development 226 10.1.5 More Streamlined Clinical Trials 227 10.1.6 Significant Growth of High-Impact Oncogenic Biomarker Research 227 10.1.7 Advancements in Discovery Technologies 227 10.2 Challenges of the Oncogenic Biomarker Market 228 10.2.1 Variability of Biomarkers within Different Cancer Subtypes 228 10.2.2 Integration of Genomics and Biomarker Diagnostics into the Healthcare System 228 10.2.3 Ethical Considerations 228 10.3 Restraints of the Cancer Biomarker Market 229 10.3.1 Initial Investment into Biomarker Discovery and Development 229 10.3.2 Are Biomarkers Profitable for Smaller Companies? 229 10.4 Opportunities for the Cancer Biomarker Market 230 10.4.1 Personalized Medicine Market Opportunities 230 10.4.2 Companion Diagnostics 230
9.11 Genelex 213 9.12 Genomic Health 213 9.13 Myriad 214 9.14 Nodality 218 9.15 Qiagen 220
10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market 225 10.1 Drivers of Oncogenic Biomarker Market 225 10.1.1 High demand and Unmet Need Enhances the Global Biomarker Market 225 10.1.2 Biomarkers are Highly Specific Diagnostic and Prognostic Clinical Tools 225 10.1.3 Increasing Cancer Prevalence Globally 226 10.1.4 FDA Support Increases Biomarker Development 226 10.1.5 More Streamlined Clinical Trials 227 10.1.6 Significant Growth of High-Impact Oncogenic Biomarker Research 227 10.1.7 Advancements in Discovery Technologies 227 10.2 Challenges of the Oncogenic Biomarker Market 228 10.2.1 Variability of Biomarkers within Different Cancer Subtypes 228 10.2.2 Integration of Genomics and Biomarker Diagnostics into the Healthcare System 228 10.2.3 Ethical Considerations 228 10.3 Restraints of the Cancer Biomarker Market 229 10.3.1 Initial Investment into Biomarker Discovery and Development 229 10.3.2 Are Biomarkers Profitable for Smaller Companies? 229 10.4 Opportunities for the Cancer Biomarker Market 230 10.4.1 Personalized Medicine Market Opportunities 230 10.4.2 Companion Diagnostics 230
Get Full Report With Table Of Contents at http://marketstoreports.com/products/global-usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipeline-analysis
About Us:
Markets to Reports is an effort to assist
you with the required market intelligence statistics matching your specific
requirements linked to various products, industries, services, companies and
trends etc. We partner with the best of the publishers across the globe
updating our database on a real time basis giving you easy access to the
information that you are interested in. We cater to conglomerates ranging from
start-ups to mid-size to Fortune 500 companies.
Our database of reports focus on various verticals/domains
including IT, Telecom & Networking, Engineering & Automation, Food
& Retail, Healthcare, Chemical, Energy, etc.
Your success is our accomplishment!
For More Information –
Please call us or write to us:
UK: +44-333-011-9100
Email: sales@marketstoreports.com
Follow Us –
Browse Blog at http://marketstoreports.blogspot.com
Browse Blog at http://marketstoreports.wordpress.com/
No comments:
Post a Comment